CoChat

Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma

Cheng, T., Grasse, L., Shah, J., Chandra, J. · 2015 · Drugs of Today
Cited by 32

The DOI matches its Crossref record.

Abstract

Histone deacetylase inhibitors (HDACis) have emerged as novel therapeutic agents for cancer. Currently, four HDACis are approved by the Food and Drug Administration (FDA) to treat various hematologic malignancies. Panobinostat (LBH-589, trade name Farydak®, developed and marketed by Novartis) is a potent pan-HDACi with demonstrated anticancer activities against multiple myeloma, a B-cell malignancy, at a low nanomolar range in preclinical settings, and in 2015 was granted FDA approval for the treatment of relapsed and refractory multiple myeloma. Here, we review the development of HDACis, the unique features of panobinostat, and the rationale for developing panobinostat in a combination setting for the treatment of multiple myeloma. We also review the completed and ongoing clinical trials testing the efficacy of panobinostat in combination therapies and highlight future therapeutically relevant strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1358/dot.2015.51.8.2362311

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 32

Metadata

Authors
Cheng, T., Grasse, L., Shah, J., & Chandra, J.
Venue
Drugs of Today
Publisher
Portico
Published
2015
Volume
51
Issue
8
Pages
491
ISSN
  • 0025-7656 (ISSN-L)
  • 1699-4019
OpenAlex
W2216387124
Cited by
32
References
0
FWCI
1.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma. https://app.cochat.ai/papers/10.1358/dot.2015.51.8.2362311
The paper
Cheng, T., Grasse, L., Shah, J., & Chandra, J. (2015). Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma. Drugs of Today. https://doi.org/10.1358/dot.2015.51.8.2362311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.